Pioglitazone in Treatment of Type 2 Diabetes:A Phase Ⅱ Clinical Trial

王颜刚,赵文娟,闫胜利,袁鹰,付正菊,杨军,李成乾,陈红

DOI: https://doi.org/10.3969/j.issn.1007-7669.2004.12.004

2004-01-01

Abstract:AIM: To compare the effect of pioglitazone and metformin in dereasing blood glucose, blood fat and improving insulin sensitivity. METHODS: The parallel double blind randomized control clinical trial was used. Sixty patients were divided into group A and group B. The patients of group A took metformin 500 mg, po, bid for 12 wk. The patients of group B took pioglitazone (30 mg), po, qd for (12 wk). The changes of blood glucose, blood fat and insulin before and after treatment between two groups were observed. RESULTS: Fifty-three patients (M 17,F 36; age (56±s 6) a) finished the trial. There were no differences in general data between 2 groups (P(0.05)). The blood glucose and glycosylated hemoglobin(HbA_(1c)) after treatment in two groups significantly reduced (P(0.01)). Insulin and C-peptide reduced in group B (P(0.01)). As to group A, postprandial insulin reduced (6±11) mU·L~(-1),P(0.05). The triglycerides reduced ((0.5)±(0.8)) mmol·L~(-1) and the free fat acid reduced (280±396) μmol·L~(-1) in group B. However, the high-density lipoprotein cholesterol was improved in two groups. Besides, the variable value of lower-density lipoprotein cholesterol and total cholesterol in group A was obviously lower than that in group B ((P(0.05)) or P(0.01)). Blood uric acid decreased ((27±44)) μmol·L~(-1) in group B. Both erythrocyte and hemoglobin in two groups were reduced (P(0.01)). There was no difference in adverse reaction rate between two groups (P(0.05)). CONCLUSION: Pioglitazone and metformin are equal efficient in decreasing blood glucose and regulating blood lipid. Moreover, pioglitazone exerts significant effects on improving insulin sensitivity and decreasing uric acid in blood.